血管的病理生理学及其药理治疗的新方法
Dalyia Abu-Ghazaleh1, David A Taylor2, Louise Roberts3
1School of Pharmacy and Medical Sciences, Griffith University, Southport, Queensland, Australia.
Journal of cardiovascular pharmacology and therapeutics
|June 21, 2025
概括
血管 (VVS) 是昏的常见原因之一. 本综述探讨了VVS机制和药理疗法,强调了当前治疗方法的有限证据,并提出了新的目标.
科学领域:
- 心脏病学 心脏病学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管 (VVS) 是一种短暂的意识丧失,通常是由压力或直立姿势引发的.
- VVS是由复杂的生理反应引起的,包括同情度的增加,心,血管扩张,导致大脑的低 perfusion.
- 目前对VVS的治疗方法,如物理机动和电动节奏,显示效果有限,需要进一步研究.
研究的目的:
- 审查和分析VVS现有的药理干预措施和临床试验.
- 通过动物模型和患者研究,研究VVS所涉及的生理机制和神经递质.
- 根据目前的理解,基于VVS药理治疗的潜在新目标.
主要方法:
- 检查使用血管反射弧动物模型的研究.
- 对用于诱导患者VVS的倾斜表测试数据的分析.
- 审查关于药理干预措施的现有文献及其在VVS中的有效性.
主要成果:
- 目前,有限的证据支持现有药理疗法的有效性,以减少VVS发作.
- 研究揭示了关键的生理机制和神经递质,涉及到血管道反射弧.
- 对激活心脏 afferent C 纤维的心脏和血小板介质的研究提供了对 VVS 病理生理学的见解.
结论:
- 需要更有效的药理疗法治疗血管.
- 了解VVS的复杂机制可以指导开发新的治疗策略.
- 对VVS病理生理学的进一步研究可能会揭示药物开发的新目标,以防止昏发作.
更多相关视频
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
8.9K
07:59Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
1.4K
相关概念视频
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
84
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
84
01:25Dysrhythmias VI: Management of Dysrhythmias
114
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
114
01:16Antianginal Drugs: Nitrates and β-Blockers
769
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
769
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
706
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
706
01:22Heart Failure Drugs: β-Blockers
445
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
445
01:28Drugs Acting on Autonomic Ganglia: Blockers
1.2K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.2K